Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032336 | 0.85 | AR (0.65) | ARPGR | |
| SCHEMBL2220553 | 0.85 | AR (0.55) | ARPGR | |
| SCHEMBL24684821 | 0.84 | AR (0.63) | ARPGR | |
| SCHEMBL8559864 | 0.81 | AR (0.61) | ARPGR | |
| SCHEMBL4026199 | 0.81 | AR (0.78) | ARPGR | |
| SCHEMBL4028958 | 0.80 | AR (0.67) | ARPGR | |
| SCHEMBL16986768 | 0.80 | AR (0.81) | ARPGR | |
| SCHEMBL7784170 | 0.79 | AR (0.61) | ARPGR | |
| SCHEMBL4027208 | 0.78 | AR (0.74) | ARPGR | |
| SCHEMBL1715956 | 0.77 | AR (1.00) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2242745-A1 | NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009097995-A1 | NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097995-A1 | NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | FABP4, GPR119, PGC | AR 3140/4885PGR 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.